Eli Lilly Expands USA Manufacturing with Alabama Plant
The site will focus on producing synthetic and peptide-based medicines, including Lilly’s first oral GLP-1 weight-loss therapy, Orforglipron, which the company expects to submit for regulatory approval early next year.
Eli Lilly | 11/12/2025 | By Darshana
FDA Approves Expanded Use of Eli Lilly's Jaypirca in Relapsed or Refractory CLL/SLL
Eli Lilly’s Jaypirca (pirtobrutinib) is the only medicine in CLL or SLL that has been prospectively studied in a randomised trial of patients previously treated with a covalent BTK inhibitor.
Eli Lilly | 04/12/2025 | By Dineshwori
Lilly Lowers Zepbound's Single-dose Vials' Cost
Lilly has reduced the price of its Zepbound (tirzepatide) single-dose vials, reinforcing its commitment to improving affordability and expanding access for people living with obesity.
Eli Lilly | 02/12/2025 | By Dineshwori
Insilico Medicine and Eli Lilly Expand Collaboration to Accelerate AI-Driven Drug Discovery
The partnership aims to combine Insilico’s advanced Pharma.AI platforms with Lilly’s deep expertise in disease biology and drug development to jointly discover and advance innovative therapies for unmet medical needs.
Eli Lilly | 11/11/2025 | By Dineshwori | 220
Eli Lilly and SanegeneBio Partner to Develop RNAi Therapies for Metabolic Diseases
SanegeneBio, a clinical-stage biotechnology company developing RNAi therapeutics, has entered into a global research and licensing collaboration with Eli Lilly and Company to advance RNAi candidates for metabolic diseases.
Eli Lilly | 10/11/2025 | By Dineshwori | 192
Eli Lilly has announced plans to invest USD 3 billion in a new manufacturing facility in Katwijk, the Netherlands, to expand its global capacity for producing oral medicines and strengthen its supply chain network.
Eli Lilly | 04/11/2025 | By Dineshwori
Eli Lilly to Pour USD 1.2B into Puerto Rico Facility Expansion Amid USA Manufacturing Push
Eli Lilly announced plans to invest more than USD 1.2 billion to expand and modernise its Lilly del Caribe manufacturing site in Carolina, Puerto Rico, as part of its broader initiative to enhance pharmaceutical production in the United States.
Eli Lilly | 03/11/2025 | By Darshana | 146
Eli Lilly And Cipla Partner to Distribute Yurpeak (Tirzepatide) in India
Eli Lilly and Cipla have signed an agreement to distribute and promote tirzepatide in India under a second brand name, Yurpeak.
Eli Lilly | 27/10/2025 | By Dineshwori | 277
Eli Lilly Reports Positive Phase 3 Topline Results for Oral GLP-1 Orforglipron in Type 2 Diabetes
Eli Lilly and Company has announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials evaluating orforglipron for the treatment of type 2 diabetes.
Eli Lilly | 16/10/2025 | By Dineshwori | 200
Eli Lilly and Company has announced plans to invest more than USD 1 billion over the next several years to expand its contract manufacturing footprint in India, aimed at enhancing global access to its innovative medicines.
Eli Lilly | 07/10/2025 | By Darshana | 153
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy